Shares of Stereotaxis Inc (OTCMKTS:STXS) traded down 3.4% during trading on Monday following insider selling activity. The company traded as low as $4.56 and last traded at $4.47, 130,713 shares traded hands during mid-day trading. A decline of 60% from the average session volume of 324,865 shares. The stock had previously closed at $4.62.

Specifically, major shareholder Paul J. Isaac sold 44,294 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $5.11, for a total transaction of $226,342.34. Following the completion of the sale, the insider now directly owns 26,000 shares in the company, valued at approximately $132,860. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Paul J. Isaac sold 39,686 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $5.22, for a total transaction of $207,160.92. Following the sale, the insider now owns 26,000 shares of the company’s stock, valued at $135,720. The disclosure for this sale can be found here. 34.91% of the stock is owned by insiders.

STXS has been the subject of a number of research reports. Lake Street Capital boosted their target price on shares of Stereotaxis from $5.00 to $9.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Cowen started coverage on shares of Stereotaxis in a research report on Sunday, April 19th. They set an “outperform” rating and a $6.00 price objective for the company. Finally, Zacks Investment Research raised shares of Stereotaxis from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Thursday, June 4th.

The business’s 50-day moving average price is $4.46 and its 200-day moving average price is $4.19.

Stereotaxis (OTCMKTS:STXS) last issued its quarterly earnings data on Tuesday, May 5th. The medical equipment provider reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). The firm had revenue of $5.76 million during the quarter. Stereotaxis had a negative net margin of 14.80% and a negative return on equity of 1,456.01%.

A number of institutional investors have recently modified their holdings of STXS. Tower Research Capital LLC TRC bought a new position in Stereotaxis in the 4th quarter worth $39,000. Citigroup Inc. boosted its holdings in Stereotaxis by 573.8% in the 1st quarter. Citigroup Inc. now owns 15,181 shares of the medical equipment provider’s stock worth $46,000 after buying an additional 12,928 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in Stereotaxis in the 4th quarter worth $70,000. Cubist Systematic Strategies LLC bought a new position in Stereotaxis in the 4th quarter worth $85,000. Finally, Jane Street Group LLC bought a new position in shares of Stereotaxis during the 1st quarter valued at about $85,000. 20.75% of the stock is owned by institutional investors.

About Stereotaxis (OTCMKTS:STXS)

Stereotaxis, Inc designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures.

Featured Article: When is a capital gain realized?

Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.